WHO IS ELIGIBLE FOR WEIGHT LOSS JABS?

SEMAGLUTIDE, sold by Danish pharmaceutical company Novo Nordisk under the brand name Wegovy, is available on the NHS for those with a body mass index (BMI) of more than 35 and at least one weight-related health complication.

- 

The drug works by binding to, and activating, the GLP-1 (glucagon-like peptide-1) receptor, a protein that controls blood sugar, appetite, and other physiological functions. This helps reduce appetite and slow the movement of food through the stomach.

Clinical trials indicate that when used alongside diet, physical activity, and behavioural support, Wegovy users can achieve up to a 15 per cent reduction in body weight after one year.